Wall Street Zen Upgrades Sana Biotechnology (NASDAQ:SANA) to Hold

Sana Biotechnology (NASDAQ:SANA) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Several other brokerages have also recently issued reports on SANA. Citizens Jmp upped their price target on shares of Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a research report on Thursday, October 30th. Wedbush increased their price objective on Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sana Biotechnology in a report on Wednesday, October 8th. HC Wainwright reduced their price target on Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday. Finally, JMP Securities set a $8.00 price objective on Sana Biotechnology in a research note on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Sana Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.33.

Sana Biotechnology Trading Up 1.0%

Sana Biotechnology stock opened at $4.09 on Friday. The stock has a 50-day moving average price of $4.06 and a two-hundred day moving average price of $3.37. Sana Biotechnology has a 12 month low of $1.26 and a 12 month high of $7.30. The company has a market capitalization of $972.64 million, a PE ratio of -4.22 and a beta of 1.94.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.03. As a group, analysts predict that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sana Biotechnology

Several large investors have recently added to or reduced their stakes in the business. Invesco Ltd. boosted its holdings in shares of Sana Biotechnology by 241.5% during the 1st quarter. Invesco Ltd. now owns 165,646 shares of the company’s stock worth $278,000 after buying an additional 117,144 shares in the last quarter. SCS Capital Management LLC acquired a new position in shares of Sana Biotechnology during the 1st quarter valued at $137,000. CWM LLC boosted its stake in Sana Biotechnology by 125.7% during the second quarter. CWM LLC now owns 86,750 shares of the company’s stock worth $237,000 after acquiring an additional 48,319 shares in the last quarter. Ieq Capital LLC grew its holdings in Sana Biotechnology by 428.7% in the first quarter. Ieq Capital LLC now owns 104,832 shares of the company’s stock worth $176,000 after purchasing an additional 85,004 shares during the period. Finally, Clearline Capital LP bought a new stake in Sana Biotechnology in the first quarter valued at $690,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.